To our Valued Patients

Lachen, SWITZERLAND
24/03/2020
Corporate news
A messsage from our Chairman and CEO on COVID-19

We hope this message finds you safe and well. As you are aware, we are in the middle of an unprecedented global health crisis, as governments and health authorities introduce increasingly restrictive measures to slow the spread of the coronavirus. We recognise that this must be a very stressful time for you, and wanted to reassure you that we are doing everything we can to ensure that you continue to receive the medicines you need to stay healthy.

Our medicines are vital to hundreds of thousands of people in at least 118 countries, many of whom are chronically ill with conditions that could put them at an increased risk from the coronavirus. We are doing everything possible to maintain our production levels and minimise any possible disruptions.

To that end, our plasma collection centres and manufacturing facilities around the world are continuing to operate as close to capacity as the situation, local regulations and the safety of our people allows.

Octapharma has established an operations task force which meets daily in order to monitor and respond to the evolving situation. In addition, we have introduced measures across our organisation and are following all applicable guidelines to ensure that our people can continue working safely.

State agencies are also playing their part. Governments and health authorities in several markets have recognised Octapharma as a manufacturer of “essential medicines” which are of critical importance to their national health systems. Many other regulatory authorities have contacted us to emphasize their willingness to support and work with us, in order to minimise any potential supply disruptions and impact on public health.

We continue to live by our mission to provide you, our patients with life-saving medicines, to the best of our ability.

Yours sincerely,

Wolfgang Marguerre

Chairman and CEO, Octapharma Group

Keywords

Haematology

Haemophilia

Immunology

Engaging with patients

COVID-19